search
Back to results

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

Primary Purpose

Diabetes Mellitus, Diabetic Retinopathy

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AEYE-DS Software
Sponsored by
AEYE Health LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetes Mellitus

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥22 Male or female Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO): Understand the study and volunteer to sign the informed consent Exclusion Criteria: Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters. Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion. Previously diagnosed with Diabetic Retinopathy. History of laser treatment of the retina or injections into either eye, or any history of retinal surgery. Currently participating in another investigational eye study and actively receiving investigational product for DR or DME. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation). Participant is contraindicated for imaging by fundus imaging systems used in the study: Participant is hypersensitive to light Participant recently underwent photodynamic therapy (PDT) Participant is taking medication that causes photosensitivity Participant has a history of angle-closure glaucoma or narrow anterior chamber angles Subject is pregnant.

Sites / Locations

  • Karas Health CareRecruiting
  • Lake Nona ResearchRecruiting
  • The Jackson ClinicRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AEYE-DS Software Device

Arm Description

An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy

Outcomes

Primary Outcome Measures

Sensitivity and Specificity

Secondary Outcome Measures

Full Information

First Posted
March 29, 2023
Last Updated
May 4, 2023
Sponsor
AEYE Health LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05857943
Brief Title
Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images
Official Title
Prospective Clinical Trial to Demonstrate the Efficacy and Safety if AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images Obtained With a Funduscopic Device
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 29, 2023 (Actual)
Primary Completion Date
December 29, 2023 (Anticipated)
Study Completion Date
March 29, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AEYE Health LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital funduscopic images using AI-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Diabetic Retinopathy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
369 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AEYE-DS Software Device
Arm Type
Experimental
Arm Description
An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy
Intervention Type
Device
Intervention Name(s)
AEYE-DS Software
Intervention Description
Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
Primary Outcome Measure Information:
Title
Sensitivity and Specificity
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥22 Male or female Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO): Understand the study and volunteer to sign the informed consent Exclusion Criteria: Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters. Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion. Previously diagnosed with Diabetic Retinopathy. History of laser treatment of the retina or injections into either eye, or any history of retinal surgery. Currently participating in another investigational eye study and actively receiving investigational product for DR or DME. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation). Participant is contraindicated for imaging by fundus imaging systems used in the study: Participant is hypersensitive to light Participant recently underwent photodynamic therapy (PDT) Participant is taking medication that causes photosensitivity Participant has a history of angle-closure glaucoma or narrow anterior chamber angles Subject is pregnant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ahava Stein
Phone
+972-9-7670002
Email
ahava@asteinrac.com
Facility Information:
Facility Name
Karas Health Care
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Burrus
Email
jessica@karashealthcare.com
Facility Name
Lake Nona Research
City
Orlando
State/Province
Florida
ZIP/Postal Code
32832
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Candida Cabrera
Email
ccabrera@lakenonarg.com
Facility Name
The Jackson Clinic
City
Jackson
State/Province
Tennessee
ZIP/Postal Code
38305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Copous
Email
lcopous@jacksonclinic.com
First Name & Middle Initial & Last Name & Degree
Kellie Wallace-Wildin, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

We'll reach out to this number within 24 hrs